到目前为止,所有用于试验的埃博拉病毒疫苗都是基于1976年扎伊尔暴发的病毒株。这里,作者旨在评估表达2014病毒流行株糖蛋白的基于腺病毒-5的新型重组型埃博拉载体疫苗的安全性及免疫原性。这项随机、双盲、安慰剂对照的一期临床试验在中国江苏省台州县开展。年龄18~60岁的健康成人被列入试验对象并用计算机生成的随机化区组(区组大小为6)进行随机化分组(2∶1),分别接受 To date, all Ebola vaccines used in the trials are based on the strain of Zaire outbreak in 1976. Here, the authors aimed to assess the safety and immunogenicity of the new recombinant adenovirus-5-based recombinant Ebola vector vaccine expressing the glycoprotein of the 2014 virus epidemic strain. This randomized, double-blind, placebo-controlled Phase I clinical trial was conducted in Taizhou, Jiangsu Province, China. Healthy adults aged 18 to 60 years were enrolled in the study and randomized (2: 1) randomized block (2: 1) in a computer-generated randomized block (block size 6)